Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
18.03
-0.85 (-4.50%)
Mar 13, 2025, 4:00 PM EST - Market closed
Spyre Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | - | 0.89 | 2.33 | 18.74 | - | Upgrade
|
| Revenue Growth (YoY) | - | -61.96% | -87.57% | - | - | Upgrade
|
| Cost of Revenue | 162.79 | 84.05 | 58.58 | 57.07 | 59.64 | Upgrade
|
| Gross Profit | -162.79 | -83.16 | -56.25 | -38.33 | -59.64 | Upgrade
|
| Selling, General & Admin | 45.78 | 34.45 | 28.53 | 27.32 | 21.84 | Upgrade
|
| Operating Expenses | 45.78 | 34.45 | 28.53 | 27.32 | 21.84 | Upgrade
|
| Operating Income | -208.57 | -117.61 | -84.78 | -65.65 | -81.48 | Upgrade
|
| Interest & Investment Income | 21.31 | 6.15 | 0.84 | 0.11 | 0.59 | Upgrade
|
| Other Non Operating Income (Expenses) | -20.71 | -102.66 | -0.01 | -0.12 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -207.97 | -214.13 | -83.95 | -65.66 | -80.89 | Upgrade
|
| Merger & Restructuring Charges | - | -10.95 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 16.45 | - | - | - | Upgrade
|
| Pretax Income | -207.97 | -338.82 | -83.95 | -65.66 | -80.89 | Upgrade
|
| Income Tax Expense | 0.05 | -0.03 | -0.14 | 0.14 | - | Upgrade
|
| Net Income | -208.02 | -338.79 | -83.82 | -65.8 | -80.89 | Upgrade
|
| Preferred Dividends & Other Adjustments | -58.46 | -243.91 | - | - | - | Upgrade
|
| Net Income to Common | -149.56 | -94.88 | -83.82 | -65.8 | -80.89 | Upgrade
|
| Shares Outstanding (Basic) | 47 | 7 | 3 | 3 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 47 | 7 | 3 | 3 | 2 | Upgrade
|
| Shares Change (YoY) | 581.85% | 104.59% | 28.19% | 23.18% | 67.05% | Upgrade
|
| EPS (Basic) | -3.18 | -13.76 | -24.86 | -25.02 | -37.89 | Upgrade
|
| EPS (Diluted) | -3.18 | -13.76 | -24.86 | -25.02 | -37.89 | Upgrade
|
| Free Cash Flow | -157.41 | -99.91 | -80.18 | -54.29 | -80.06 | Upgrade
|
| Free Cash Flow Per Share | -3.35 | -14.49 | -23.78 | -20.64 | -37.50 | Upgrade
|
| Gross Margin | - | - | - | -204.55% | - | Upgrade
|
| Operating Margin | - | -13274.49% | -3640.23% | -350.33% | - | Upgrade
|
| Profit Margin | - | -10709.14% | -3598.75% | -351.14% | - | Upgrade
|
| Free Cash Flow Margin | - | -11276.52% | -3442.77% | -289.71% | - | Upgrade
|
| EBITDA | -207.82 | -116.87 | -83.21 | -64.07 | -80.49 | Upgrade
|
| D&A For EBITDA | 0.74 | 0.74 | 1.57 | 1.58 | 1 | Upgrade
|
| EBIT | -208.57 | -117.61 | -84.78 | -65.65 | -81.48 | Upgrade
|
| Revenue as Reported | - | 0.89 | 2.33 | 18.74 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.